Eris Lifesciences
Ticker > Company >

Eris Lifesciences share price

Eris Lifesciences Ltd.

NSE: ERIS BSE: 540596 SECTOR: Pharmaceuticals & Drugs  1.03 L   299   43

1676.90
+13.95 (0.84%)
BSE: Today, 09:09 AM

Price Summary

Today's High

₹ 1676.9

Today's Low

₹ 1676.9

52 Week High

₹ 1909.55

52 Week Low

₹ 1130.05

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 22841.65 Cr.

Enterprise Value

₹ 24962.14 Cr.

No. of Shares

13.62 Cr.

P/E

142.46

P/B

8.77

Face Value

₹ 1

Div. Yield

0.44 %

Book Value (TTM)

₹  191.22

CASH

₹ 92.46 Cr.

DEBT

₹ 2212.95 Cr.

Promoter Holding

54.83 %

EPS (TTM)

₹  11.77

Sales Growth

14.2%

ROE

3.08 %

ROCE

6.96%

Profit Growth

-74.18 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Eris Lifesciences Ltd.

GLIMISAVE ERITEL OLMIN TENDIA RENERVE REMYLIN RABONIK TAYO LNBLOC CYBLEX ATORSAVE ROSIFLEX CREVAST RARICAP SERLIFT

Index Presence

The company is present in 20Indices.

NFT500MOM50

Nifty500 Momentum 50
52587.1
  122 (0.232535533144884%)

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
46786.75
  173.75 (0.372750091176277%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
44997.95
  52.0999999999985 (0.115917264886511%)

NFT500MULTI

Nifty500 Multifactor MQVLv 50
31631.5
  102.700000000001 (0.325733932150918%)

NIFTY500

Nifty 500
23419.1
  49.7999999999993 (0.213100092856866%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
20281.45
  64.6500000000015 (0.319783546357488%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
18061.75
  49.0999999999985 (0.272586210246684%)

NIFTYSMALLCAP250

Nifty Smallcap 250
17441.2
  59 (0.339427690395921%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
16351.4
  40.2999999999993 (0.247071012991151%)

NFT500EQUAL

Nifty 500 Equal Weight
14632.95
  47.2000000000007 (0.323603517131454%)

NIFTYTOTALMCAP

Nifty Total Market index
13183.85
  29.1499999999996 (0.221593802975351%)

SMLCAP

S&P Bse Small Cap
54458.26
  198.220000000001 (0.365314879974288%)

BSE HC

S&P Bse Healthcare
44864.7
  88.5299999999988 (0.197716776580048%)

BSE500MOM50

BSE 500 Momentum 50
43890.95
  141.939999999995 (0.324441627364824%)

BSE500

S&P Bse 500
36806.63
  109.239999999998 (0.297677845754141%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
12296.73
  40.9300000000003 (0.333964327094116%)

BSE1000

Bse 1000
10969.47
  33.4200000000001 (0.305594798853326%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SML250

S&P Bse 250 SmallCap
6978.66
  22.3899999999994 (0.321867897594541%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.2%
3 Year11.78%
5 Year10.72%

Profit Growth

1 Year-74.18%
3 Year-42.97%
5 Year-23.29%

ROE%

1 Year3.08%
3 Year11.66%
5 Year16.67%

ROCE %

1 Year6.96%
3 Year12.56%
5 Year18.24%

Debt/Equity

0.8835

Price to Cash Flow

32.54

Interest Cover Ratio

1.5451

CFO/PAT (5 Yr. Avg.)

1.37745695647524

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 54.83 16.93
Mar 2025 54.85 18.51
Dec 2024 54.86 18.51
Sep 2024 54.87 18.51
Jun 2024 54.88 18.51
Investors List
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 33.8453011984528% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -39.2999 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.37745695647524.

 Limitations

  • The company has shown a poor profit growth of -42.9683033654556% for the Past 3 years.
  • The company has shown a poor revenue growth of 11.7750960374481% for the Past 3 years.
  • The company is trading at a high PE of 142.46.
  • The company is trading at a high EV/EBITDA of 39.1222.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 456.69 436.56 399.73 404.77 578.64
Total Expenditure 333.31 293.93 300.16 283.8 362.32
Operating Profit 123.38 142.63 99.57 120.97 216.32
Other Income 5.16 5.81 7.79 16.75 22.68
Interest 56.17 56.26 54.65 53.16 45.14
Depreciation 45.55 46.16 46.68 43.38 37.6
Exceptional Items 0 0 0 0 0
Profit Before Tax 26.82 46.02 6.03 41.18 156.26
Tax 9.78 17.92 4.25 10.71 56.27
Profit After Tax 17.04 28.1 1.78 30.47 99.99
Adjusted EPS (Rs) 1.25 2.06 0.13 2.24 7.34

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 1108.83 1215.73 1330.73 1486.71 1697.75
Total Expenditure 691.36 731.68 825.61 1032.89 1211.2
Operating Profit 417.47 484.06 505.11 453.82 486.55
Other Income 10 28.99 17.26 34.83 35.51
Interest 0.94 3.05 20.81 57.42 220.24
Depreciation 37.64 51.46 64.66 102.39 181.77
Exceptional Items 0 0 0 0 0
Profit Before Tax 388.89 458.54 436.91 328.84 120.05
Tax 38.29 41.35 38.9 29.12 42.66
Net Profit 350.61 417.19 398.01 299.72 77.39
Adjusted EPS (Rs.) 25.82 30.69 29.27 22.04 5.68

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 13.58 13.59 13.6 13.6 13.62
Total Reserves 1561.89 1904.96 2208.29 2510.42 2501.28
Borrowings 0 0 209.47 485.94 1632.64
Other N/C liabilities -161.82 -170.49 -205.26 -225.97 -202.41
Current liabilities 212.42 249.79 361.73 2322.55 1010.95
Total Liabilities 1626.08 1997.86 2587.83 5106.54 4956.08
Assets
Net Block 584.32 642 897.81 1515.56 2412.18
Capital WIP 0 0 0 0 0
Intangible WIP 1.56 2.98 0.34 0.61 0.27
Investments 480.97 678.18 966.52 1618.95 991.27
Loans & Advances 25.36 11.14 85.95 27.04 268.64
Other N/C Assets 42.27 0 7.18 7.08 639.17
Current Assets 491.6 663.56 630.03 1937.3 644.55
Total Assets 1626.08 1997.86 2587.83 5106.54 4956.08
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 388.89 458.54 436.91 328.83 120.05
Adjustment 36.11 31.04 73.7 144.12 393.56
Changes in Assets & Liabilities 38.44 -37.26 -110.5 -63.18 201.69
Tax Paid -68.04 -82.9 -77.79 -73.48 -13.44
Operating Cash Flow 395.41 369.41 322.33 336.29 701.86
Investing Cash Flow -347.86 -267.64 -513.3 -2491.89 -358.99
Financing Cash Flow -81.13 -88.42 193.75 2160.05 -310.46
Net Cash Flow -33.58 13.36 2.78 4.45 32.41

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 54.88 54.87 54.86 54.85 54.83
amit indubhusan bakshi 42.87 42.86 42.85 42.84 42.83
inderjeet singh negi 4.37 4.36 4.36 4.36 4.36
kaushal kamleshkumar shah... 3.28 3.28 3.28 3.28 3.28
rajendrakumar rambhai pat... 4.37 4.36 4.36 4.36 4.36
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 45.12 45.13 45.14 45.15 45.17
bhikhalal chimanlal shah 2.76 1.97 1.97 1.97 1.97
franklin india smaller co... 1.46 3.59 3.55 3.37 3.45
hdfc small cap fund 7.76 7.54 7.42 7.82 8.08
hetal rasiklal shah 2.40 2.20 2.20 2.20 2.18
lilac investments limited... - 7.26 8.79 8.79 8.79
llp - 0.04 0.03 0.05 0.06
rakesh shah 4.88 2.92 1.45 1.45 1.45
uti-flexi cap fund - - - 3.00 2.27
uti flexi cap fund 3.95 3.81 3.41 - -
emerald investments limit... 7.27 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit FITCH
Credit FITCH
Credit FITCH
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research HDFC Securities
Research BOB Capital Market
Research BOB Capital Market
Research Ventura
Research BP Wealth
Research BP Wealth
Research HDFC Securities
Research HDFC Securities
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research HDFC Securities
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research Prabhudas Lilladhar

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY20
Concall Q3FY22
Concall Q1FY22
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY22
Presentation Q4FY21
Presentation Q4FY20
Presentation Q4FY19
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY22
Presentation Q1FY21

Company News

Eris Lifesciences receives ANVISA approval for sterile injectable facility in Ahmedabad 26 Aug, 12:58 PM Eris Lifesciences receives approval for manufacturing unit in Ahmedabad campus 25 Aug, 2:23 PM Eris Lifesciences - Quaterly Results 5 Aug, 1:25 PM Eris Lifesciences - Quaterly Results 5 Aug, 1:25 PM Eris Lifesciences - Quaterly Results 5 Aug, 1:25 PM Eris Lifesciences informs about investor presentation 19 May, 5:38 PM Eris Lifesciences - Quaterly Results 19 May, 4:10 PM Eris Lifesciences - Quaterly Results 19 May, 4:10 PM Eris Lifesciences - Quaterly Results 19 May, 4:10 PM Eris Lifesciences informs about investor call 13 May, 5:33 PM Eris Lifesciences submits analyst meet intimation 13 May, 5:04 PM Eris Lifesciences informs about board meeting 13 May, 4:47 PM Eris Lifesciences Informs about clarification on increase in volume 21 Mar, 4:51 PM Eris Lifesciences informs about allotment of ESOP 6 Mar, 2:24 PM Eris Lifesciences informs about analyst meet 24 Feb, 11:46 AM Eris Lifesciences informs about disclosure 21 Feb, 9:35 AM Eris Lifesciences - Quaterly Results 4 Feb, 12:45 PM Eris Lifesciences - Quaterly Results 4 Feb, 12:45 PM Eris Lifesciences - Quaterly Results 4 Feb, 12:45 PM Eris Lifesciences informs about board meeting 29 Jan, 2:52 PM Eris Lifesciences informs about investor meet 4 Dec, 5:17 PM Eris Lifesciences - Quaterly Results 25 Oct, 1:21 PM Eris Lifesciences - Quaterly Results 25 Oct, 1:21 PM Eris Lifesciences - Quaterly Results 25 Oct, 1:21 PM Eris Lifesciences acquires 100% stake in Chemman Labs 15 Oct, 12:15 PM Eris Lifesciences informs about analyst meet 13 Sep, 3:19 PM Eris Lifesciences informs about disclosure 26 Aug, 5:26 PM Eris Lifesciences informs about disclosure 26 Aug, 5:05 PM Eris Lifesciences to acquire 100% stake in Chemman Labs 2 Aug, 4:11 PM Eris Lifesciences - Quaterly Results 2 Aug, 2:31 PM Eris Lifesciences - Quaterly Results 2 Aug, 2:31 PM Eris Lifesciences - Quaterly Results 2 Aug, 2:31 PM Eris Lifesciences informs about allotment of equity shares under ESOP 24 Jun, 2:30 PM Eris Lifesciences completes acquisition of 19% equity stake in Swiss Parenterals 12 Jun, 10:14 AM Eris Lifesciences informs about analyst meet 31 May, 4:23 PM Eris Lifesciences gets nod to raise up to Rs 1250 crore via NCDs 21 May, 6:14 PM Eris Lifesciences - Quaterly Results 21 May, 4:53 PM Eris Lifesciences - Quaterly Results 21 May, 4:53 PM Eris Lifesciences - Quaterly Results 21 May, 4:53 PM Eris Lifesciences informs about update on board meeting 17 May, 3:45 PM Eris Lifesciences planning to raise funds 17 May, 12:44 PM Eris Lifesciences informs about analyst meet 21 Mar, 4:50 PM Eris Lifesciences acquires Biocon Biologics’ India branded formulation business 15 Mar, 10:59 AM Eris Lifesciences informs about outcome of board meeting 14 Mar, 4:56 PM Eris Lifesciences informs about transcript of investor call 20 Feb, 3:35 PM Eris Lifesciences acquires 51% stake in Swiss Parenterals 16 Feb, 11:53 AM Eris Lifesciences - Quaterly Results 13 Feb, 3:35 PM Eris Lifesciences - Quaterly Results 13 Feb, 3:35 PM Eris Lifesciences - Quaterly Results 13 Feb, 3:35 PM Eris Lifesciences informs about disclosure 9 Nov, 10:39 AM

Eris Lifesciences Stock Price Analysis and Quick Research Report. Is Eris Lifesciences an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Eris Lifesciences. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Eris Lifesciences has a PE ratio of 141.183566671198 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Eris Lifesciences has ROA of 1.5382% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Eris Lifesciences has a Current ratio of 0.6376.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Eris Lifesciences has a ROE of 3.081%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Eris Lifesciences has a Debt to Equity ratio of 0.8835 which means that the company has low proportion of debt in its capital.

  • Sales growth: Eris Lifesciences has reported revenue growth of 14.1951% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Eris Lifesciences for the current financial year is 28.6585186275953%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Eris Lifesciences is Rs 7.35 and the yield is 0.4425%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Eris Lifesciences is Rs 11.7712. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Eris Lifesciences in Ticker for free. Also, one can get the intrinsic value of Eris Lifesciences by using Valuation Calculators, which are available with a Finology ONE subscription. 

Eris Lifesciences FAQs

Q1. What is Eris Lifesciences share price today?
Ans: The current share price of Eris Lifesciences is Rs 1661.9.

Q2. What is the market capitalisation of Eris Lifesciences?
Ans: Eris Lifesciences has a market capitalisation of Rs 22637.33053926 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Eris Lifesciences?
Ans: The PE ratio of Eris Lifesciences is 141.183566671198 and the P/B ratio of Eris Lifesciences is 8.69085015957717, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Eris Lifesciences share?
Ans: The 52-week high share price of Eris Lifesciences is Rs 1910, and the 52-week low share price of Eris Lifesciences is Rs 1097.2.

Q5. Does Eris Lifesciences pay dividends?
Ans: Currently, Eris Lifesciences pays dividends. Dividend yield of Eris Lifesciences is around 0.4425%.

Q6. What are the face value and book value of Eris Lifesciences shares?
Ans: The face value of Eris Lifesciences shares is Rs 1, while the book value per share of Eris Lifesciences is around Rs 191.2241. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Eris Lifesciences?
Ans: Eris Lifesciences has a total debt of Rs 2212.95 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Eris Lifesciences?
Ans: The ROE of Eris Lifesciences is 3.081% and ROCE of Eris Lifesciences is 6.958%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Eris Lifesciences a good buy for the long term?
Ans: The Eris Lifesciences long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Eris Lifesciences undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Eris Lifesciences appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Eris Lifesciences’s financials?
Ans: You can review Eris Lifesciences’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Eris Lifesciences

Eris Lifesciences Ltd. Financials: Check Share price, Balance Sheet, Annual report, and Quarterly Results for company analysis

Eris Lifesciences Ltd.'s stock analysis page provides long-term investors with the necessary tools and resources to make informed investment decisions. These tools and resources include share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders analysis. Our website also offers pre-built screening tools to analyze the stock's performance compared to its peers and premium feature tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. Annual reports and quarterly results are provided as downloadable documents for in-depth analysis.

Eris Lifesciences Ltd. Share Price Analysis:


When assessing long-term investment opportunities, analyzing Eris Lifesciences Ltd.'s share price is a critical factor. Our stock analysis page provides historical share price charts, which are a valuable resource for users to monitor the company's performance over time. Further analysis of this data can then be conducted using our pre-built screening tools to help investors analyze Eris Lifesciences Ltd.'s share price performance better. The analysis includes tracking the company's stock prices regularly, charting trends and assessing the future performance potential. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions. 

Eris Lifesciences Ltd. Balance Sheet Analysis:


Eris Lifesciences Ltd.'s balance sheet is a crucial indicator of the company's financial strength and stability. A thorough analysis of the balance sheet is essential for investors to understand the company's financial health and assess growth potential accurately. Our website offers access to Eris Lifesciences Ltd.'s balance sheet as a downloadable document, which users can use to perform an in-depth analysis for long-term investment decisions. Further analysis can be conducted using our premium feature tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis.

Eris Lifesciences Ltd. Annual Report Analysis:


Eris Lifesciences Ltd.'s annual report provides critical information for long-term investors regarding the company's strategic initiatives and financial performance. Understanding the annual report is essential for long-term investors since it offers insights into the company's future growth trajectory. Our website offers access to Eris Lifesciences Ltd.'s annual report as a downloadable document, which investors can use for an in-depth analysis of the company's performance. Our pre-built screening tools can assist investors in analyzing the company's performance compared to its peers, which can allow for better decision-making.

Eris Lifesciences Ltd. Dividend Analysis:


Dividend payout policies are an essential factor for long-term investors considering the viability of investing in any company's stock. Eris Lifesciences Ltd.'s dividend payout trends are a factor that investors should consider when assessing the stock's potential. Ticker features insights into Eris Lifesciences Ltd.'s dividend payout trends, which can assist long-term investors in analyzing the stock's viability as a long-term investment option.

Eris Lifesciences Ltd. Quarterly Results Analysis:


Eris Lifesciences Ltd.'s quarterly results hold critical information regarding the company's financial performance, including revenue, profits, and losses. The data from these reports can be used by long-term investors to assess the company's growth potential. Our website provides a downloadable copy of Eris Lifesciences Ltd.'s quarterly results, which investors can use to make informed analysis of the company's financial health for long-term investment decisions. Further analysis of this data can be conducted using our premium feature tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Eris Lifesciences Ltd. Stock Price Analysis:


Monitoring Eris Lifesciences Ltd.'s stock prices is critical to analyzing the stock's overall performance. Our stock analysis page features current stock price updates which investors can access to assess market trends and potential investment opportunities. Ticker's pre-built screening tools can help investors analyze the stock's performance compared to its peers and help investors make informed investment decisions for the long term. Our website provides pre-built screening tools to help investors analyze stock price and performance.

Eris Lifesciences Ltd. Price Chart Analysis:


A visual representation of Eris Lifesciences Ltd.'s share price trends over a period is an essential tool for long-term investors. It helps investors track the company's performance over time and make informed investment decisions. Ticker provides investors with a price chart to visualize Eris Lifesciences Ltd.'s share price trends over a specific period. Our pre-built screening tools can assist investors in analyzing the company's performance compared to its peers, which can allow for better decision-making.

Eris Lifesciences Ltd. News Analysis:


Keeping up with Eris Lifesciences Ltd.'s recent news and developments is crucial for investors. Our website provides timely news articles related to Eris Lifesciences Ltd. to provide investors with up-to-date insights into the stock's performance. The news section of our website offers reliable information on important events, regulatory changes, and other factors that may impact the stock's performance. Our pre-built screening tools can also provide investors with information about the company's global and local news.

Eris Lifesciences Ltd. Concall Transcripts Analysis:


Eris Lifesciences Ltd.'s concall transcripts provide investors with insights into the company's future guidance and outlook. Our website provides access to these critical documents, allowing long-term investors to stay informed on the company's financial health and future growth. Further analysis of this data can be conducted using our premium feature tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Eris Lifesciences Ltd. Investor Presentations Analysis:


Eris Lifesciences Ltd. prepares investor presentations to provide investors with detailed information on the company's operations and performance. These presentations serve as essential resources for long-term investors to study the company's strategic initiatives, offering necessary insights that can impact the stock's value. Our website offers access to these presentations, which investors can download for an in-depth analysis. Our premium feature tools can assist investors in performing an in-depth analysis of the presented data.

Eris Lifesciences Ltd. Promoters and Shareholders Analysis:


Assessing the viability of investing in Eris Lifesciences Ltd.'s stock requires considering the company's promoters and shareholders. Our stock analysis page features essential information about the company's promoters and other shareholders. Long-term investors must consider these elements before making informed investment decisions. Further analysis of the company's shareholding patterns can be conducted using our pre-built screening tools. 

Eris Lifesciences Balance Sheet Overview

Eris Lifesciences has shown significant growth on its balance sheet from March 2020 to March 2024. Particularly noteworthy is the increase in total liabilities from Rs. 1,372.59 Cr. in March 2020 to Rs. 5,106.54 Cr. by March 2024. This growth is largely attributed to a rise in current liabilities which saw an exponential increase, particularly from March 2023.

Eris Lifesciences Reserves Growth

The reserves of Eris Lifesciences have consistently increased, rising from Rs. 1,286.12 Cr. in March 2020 to Rs. 2,510.42 Cr. in March 2024. This indicates a strong retention of earnings which could signify reinvestment into the company and a robust financial health.

Eris Lifesciences Debt Analysis

The company introduced borrowings into its financial structure starting in March 2023 with Rs. 209.47 Cr., escalating to Rs. 485.94 Cr. by March 2024. This shift suggests a new leverage strategy that might be aimed at funding expansion or other significant investments.

Eris Lifesciences Asset Growth

The asset base of Eris Lifesciences has doubled over the four years, with a significant portion of the growth invested in net block and investments. From Rs. 600.64 Cr. in March 2020, the net block grew to Rs. 1,515.56 Cr. by March 2024, complemented by an increase in investments from Rs. 246.03 Cr. to Rs. 1,618.95 Cr.

This analysis is based on the Standalone Balance Sheet of Eris Lifesciences.

Investors looking into Eris Lifesciences might also consider examining more extensive market trends, including sector performance on major indices like NSE and BSE.

Read More
X